Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis - Reply

被引：0
|
作者：
Kleinschmidt-DeMasters, BK [1 ]
Tyler, KL [1 ]
机构：
[1] Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2005年 / 353卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1745 / 1745
页数：1
相关论文
共 50 条
  • [41] Progressive multifocal leukoencephalopathy associated with natalizumab in multiple sclerosis. Cidofovir and maraviroc therapeutic experience
    Belchi, O.
    Perkal, H.
    Beltran, B.
    Laguillo, G.
    Quiles, A.
    Robles-Cedeno, R.
    Ramio-Torrenta, L.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 796 - 796
  • [42] Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
    Sinnecker, Tim
    Othman, Jalal
    Kuehl, Marc
    Metz, Imke
    Niendorf, Thoralf
    Kunkel, Annett
    Paul, Friedemann
    Wuerfel, Jens
    Faiss, Juergen
    CASE REPORTS IN NEUROLOGICAL MEDICINE, 2016, 2016
  • [43] Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy"
    Dalla Costa, Gloria
    Martinelli, Vittorio
    Furlan, Roberto
    Comi, Giancarlo
    ANNALS OF NEUROLOGY, 2019, 86 (02) : 324 - 324
  • [44] Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy
    Serana, Federico
    Chiarini, Marco
    Sottini, Alessandra
    Bertoli, Diego
    Giustini, Viviana
    Tessitore, Marion Vaglio
    Caimi, Luigi
    Capra, Ruggero
    Imberti, Luisa
    JOURNAL OF NEUROIMMUNOLOGY, 2014, 277 (1-2) : 6 - 12
  • [45] Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis
    Rath, Louise
    Vijiaratnam, Nirosen
    Skibina, Olga
    INTERNAL MEDICINE JOURNAL, 2017, 47 (02) : 194 - 199
  • [46] Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients
    Dalla Costa, Gloria
    Martinelli, Vittorio
    Moiola, Lucia
    Sangalli, Francesca
    Colombo, Bruno
    Finardi, Annamaria
    Cinque, Paola
    Kolb, Eva-Maria
    Haghikia, Aiden
    Gold, Ralf
    Furlan, Roberto
    Comi, Giancarlo
    ANNALS OF NEUROLOGY, 2019, 85 (04) : 606 - 610
  • [47] Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
    Clifford, David B.
    DeLuca, Andrea
    Simpson, David M.
    Arendt, Gabriele
    Giovannoni, Gavin
    Nath, Avindra
    LANCET NEUROLOGY, 2010, 9 (04): : 438 - 446
  • [48] Magnetic resonance imaging changes following natalizumab discontinuation in multiple sclerosis patients with progressive multifocal leukoencephalopathy
    Hodel, Jerome
    Bapst, Blanche
    Outtervck, Olivier
    Verclytte, Sebastien
    Deramecourt, Vincent
    Benadjaoud, Mohamed Amine
    Pruvo, Jean-Pierre
    Vermersch, Patrick
    Leclerc, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (14) : 1902 - 1908
  • [49] Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy
    Vennegoor, Anke
    van Rossum, Johannis A.
    Polman, Chris H.
    Wattjes, Mike P.
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (12) : 1600 - 1603
  • [50] Benefit of Additional Screening for Progressive Multifocal Leukoencephalopathy in Patients With Multiple Sclerosis Taking Natalizumab: A Decision Analysis
    Landy, David C.
    Hecht, Eric M.
    CLINICAL NEUROPHARMACOLOGY, 2014, 37 (02) : 45 - 51
12345